Influenza A VIRus and Destabilization of Atherosclerotic Carotid Plaques

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-18

Study Completion Date

2023-03-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Atherosclerosis is the main cause of cardiovascular diseases and is characterized by the accumulation of lipids and inflammatory cells such as macrophages and lymphocytes within the vessel wall of large and medium-sized arteries, forming so-called plaques. The underlying molecular mechanisms are not yet clearly understood. In particular, it is not yet clear what factors can cause the "destabilization" of atherosclerotic plaques, thus making them more vulnerable and prone to triggering acute cardiovascular events. Infectious agents have also been implicated in the pathogenesis of atherosclerosis. Some of them would be able to spread from the infected tissue and migrate to endothelial cells, promoting the secretion of inflammatory mediators and the oxidation of low-density lipoproteins (LDL), their accumulation in vascular cells and the formation of foam cells , fundamental mechanisms especially in the formation of vulnerable plaques.

Recently, many studies have shown that the influenza virus can also play a role in the destabilization of atherosclerotic plaques. However, the role of influenza A virus (IVA) infection and related vaccination in the destabilization of atherosclerotic plaques is still controversial. Furthermore, the underlying molecular mechanisms are still a matter of investigation.

Based on these data, we hypothesized that IV A infection may promote the destabilization of atherosclerotic plaques through a chronic postinfection immune response. This response would lead to systemic and local changes in the expression of pro-atherosclerotic cytokines and chemokines resulting in increased recruitment of monocyte macrophages and upregulation of the expression of scavenger receptors on the surface of macrophages with greater affinity for oxidized LDL (CD36 and Lectins- Like-oxLDL-receptor 1).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

T-Mem GEne in Atherosclerosis

NCT06230406

Atherosclerosis

RECRUITING

Contribution of Hepatic and Intestinal Lipoproteins to Human Atherosclerosis

NCT01321476

Heart Disease

WITHDRAWN

Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque

NCT00636766

Carotid Atherosclerosis Stroke Type 2 Diabetes +1 more

COMPLETED NA

Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.

NCT05708547

Coronary Atherosclerosis

COMPLETED

PIPAF Platelets in the Pathogenesis of Ageing Associated Frailty

NCT05798637

Coronary Artery Disease Diabetes Mellitus, Type 2 Alzheimer Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The following data will be collected anonymously from the medical records:

* personal details (age, sex);
* comorbidity (presence of cardiovascular risk factors: arterial hypertension, smoking, dyslipidemia, ischemic heart disease, COPD, diabetes mellitus; chronic renal failure, history of cerebrovascular ischemic events);
* history of flu vaccination;
* clinical (weight, height); As per clinical practice, patients will undergo carotid endarterectomy surgery. Upon entry into the operating room, patients will be taken 4 ml of blood in 4 tubes with a specific anticoagulant (EDTA), from a peripheral venous access already positioned for the surgical procedure regardless of the study. These blood samples will be stored and processed appropriately for individual analyses.

Samples of atherosclerotic plaque removed during surgery will also be stored appropriately for subsequent investigations.

The data collected will be entered into the dedicated e-CRF and appropriately analyzed.

Use of blood samples Peripheral blood mononuclear cells (PBMC) will be separated and isolated from the venous blood sample using a Percoll gradient. These cells will be appropriately stimulated with influenza A virus antigens using specific commercial kits. This process will allow the evaluation of immune reactivity to the virus, both in the group of patients with vulnerable carotid plaque (group A) and in those with non-vulnerable plaque (group B). On the serum of the same samples, the quantitative expression of some cytokines/chemokines involved in inflammation and the atherosclerotic process (IL-6, IL-1β, TNF-α, IFN-γ, MCP-1) will be evaluated using the ELISA method).

The appropriate antibody evaluation will also be performed to test for any acute IV A infections.

Use of vascular samples Histology investigations will be carried out on atherosclerotic plaque samples which will allow determining the vulnerability or otherwise of the plaque, in such a way as to define the two groups of patients (A, vulnerable plaque; B, non-vulnerable plaque) to be analysed. and compare.

Western-Blot assays and immunohistochemical analyzes will also be performed on the same samples to evaluate the quantitative and qualitative expression of some molecules (V-CAM, I-CAM, E-Selectins) and receptors that identify scavenger macrophage cells (CD36 and Lectins -Like Ox-LDL-Receptor 1.

Finally, the same samples will be subjected to ELISA analysis for the quantitative research of the same cytokines/chemokines evaluated on the blood sample via RT-PCR. The possible presence of viral RNA will be evaluated on the atherosclerotic plaques by one step RT-PCR, as well as the T-specific cell reactivity to the IV A virus after the preparation of appropriate cell cultures which will be stimulated with the same commercial kit used to stimulate the PMBC of peripheral blood, according to the method described by Keller et al. Collaterally, the possible presence of viral or bacterial DNA in the plaques will be checked. In particular, the presence of DNA from Human Polyomaviruses and Human Herpesviruses (herpes simplex virus 7 and 2, varicella zoster virus, Epstein-Barr virus, human cytomegalovirus, human herpesvirus 6) and Chlamydia will be analyzed through Real Time PCR.

Evaluation of specific T-cell reactivity to virus IV A Taking as reference the method described by Keller et al, the stimulation index (SI) will be evaluated, both on the blood sample and on the atherosclerotic plaque, as the average count per minute (cpm) of cultures with the virus, divided by the mean cpm of parallel cultures without viruses.

Subsequently, the reactivity will be calculated based on the ratio between the SI of the plaque T cells and the SI of the peripheral blood T cells for each patient, defining responsive patients if the ratio is \> 2 (patients with SI of the T cells T of the plaque significantly higher than those of the peripheral blood), and not responsive if the ratio is \< 2 (in the latter case, patients with SI of the T cells of the peripheral blood greater than those of the plaque, or with SI of the T cells Plaque T not significantly higher than those of peripheral blood).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atherosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carotid Endoarterectomy

Surgical removal of atherosclerotic plaque from the carotid artery, collection of blood samples

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adult patients (age \> 18 years) who have given their consent to participate in the study, belonging to the Vascular Surgery Unit of the IRCCS Policlinico San Donato to undergo carotid endarterectomy surgery for significant carotid stenosis (in accordance with the Guidelines International guidelines, asymptomatic patients with carotid stenosis \> 80% according to ECST and symptomatic patients with stenosis \> 70% according to ECST